Multiple Myeloma Treatment - Ninlaro

March 23, 2019 9:30 am to 12:00 pm




NINLARO® (ixazomib) is a prescription medicine used to treat multiple myeloma in combination with the medicines REVLIMID® (lenalidomide) and dexamethasone, in people who have received at least one prior treatment for their multiple myeloma.

It is not known if NINLARO is safe and effective in children.

Hear a healthcare professional speak about multiple myeloma and NINLARO

Hear the story and treatment experience of a person living with multiple myeloma

Patient & Caregiver




Saturday, March 23, 2019
Registration: 9:30 AM
Program Start: 10:00 AM

DoubleTree by Hilton Campbell-Pruneyard Plaza
1995 S. Bascom Avenue
Campbell, CA 95008



FEATURING: Sam Mazj, MD, FACP, Feather River Hospital
                       & a NINLARO Patient Ambassador




Friends and family are welcome!
Complimentary parking and light fare provided.

Important Safety Information for NINLARO® (ixazomib)
NINLARO may cause serious side effects, including:



Low platelet counts (thrombocytopenia) are common with NINLARO and can sometimes be serious. You may need platelet transfusions if your counts are too low. Tell your healthcare provider if you have any signs of low platelet counts, including bleeding and easy bruising.




Stomach and intestinal (gastrointestinal) problems. Diarrhea, constipation, nausea, and vomiting are common with NINLARO and can sometimes be severe. Call your healthcare provider if you get any of these symptoms and they do not go away during treatment with NINLARO. Your healthcare provider may prescribe medicine to help treat your symptoms.




Nerve problems are common with NINLARO and may also be severe. Tell your healthcare provider if you get any new or worsening symptoms including: tingling, numbness, pain, a burning feeling in your feet or hands, or weakness in your arms or legs.




Swelling is common with NINLARO and can sometimes be severe. Tell your healthcare provider if you develop swelling in your arms, hands, legs, ankles, or feet, or if you gain weight from swelling.




Skin Reactions. Tell your healthcare provider if you get a new or worsening rash.




Liver problems. Tell your healthcare provider if you get these signs of a liver problem: yellowing of your skin or the whites of your eyes; pain in your right upper-stomach area.



Other common side effects have occurred. Tell your healthcare provider if you get new or worsening back pain, lowered white blood cells (neutropenia) that may increase the risk of infection, or vision conditions such as blurred vision, dry eye, or pink eye (conjunctivitis).

These are not all the possible side effects of NINLARO. Talk to your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Before taking NINLARO, tell your healthcare provider about all your medical conditions, including if:




You have liver problems or kidney problems or are on dialysis.




You or your partner are pregnant or plan to become pregnant. NINLARO can harm your unborn baby. Avoid becoming pregnant during treatment with NINLARO. You and your partner should use effective birth control during treatment and for 90 days after the final dose of NINLARO. If using hormonal contraceptives (for example, the pill), an additional barrier method of contraception (for example, diaphragm or condom) must be used.




You are breastfeeding or plan to breastfeed. Do not breastfeed during treatment with NINLARO and for 90 days after your final dose of NINLARO.



Tell your healthcare provider about all the medications (prescription and over-the-counter) and nutritional supplements you are taking or before starting any new medicines.

Please see Patient Information in the NINLARO (ixazomib) full Prescribing Information.

To unsubscribe from this and future communications from Takeda Oncology, click here.

All trademarks are the property of their respective owners
©2018 Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of
Takeda Pharmaceutical Company Limited.
All rights reserved. 04/18 MAT-US-IXA-18-00094